168
Participants
Start Date
February 28, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
October 31, 2028
SCTB35 injection
SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.
RECRUITING
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Xuanwu Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Jilin Provincial People's Hospital, Changchun
NOT_YET_RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
NOT_YET_RECRUITING
Zhejiang Provincial People's Hospital, Hangzhou
NOT_YET_RECRUITING
The First People's Hospital of Jiujiang City, Jiujiang
NOT_YET_RECRUITING
The First Affiliated Hospital of Kunming Medical University, Kunming
NOT_YET_RECRUITING
Linfen Central Hospital, Linfen
NOT_YET_RECRUITING
Mianyang Central Hospital, Mianyang
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Pingxiang People's Hospital, Pingxiang
NOT_YET_RECRUITING
Shanxi Bethune Hospital, Taiyuan
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
Xinxiang Central Hospital, Xinxiang
Sinocelltech Ltd.
INDUSTRY